No spam - just the good stuff

Subscribe to our newsletter

News

Biotech

Overcoming the ‘perfect storm’ in regenerative medicine

Autophagy-inducing drug bags funding boost from The Michael J Fox Foundation

Tapping the potential of mRNA in cellular reprogramming and beyond

Eterna Therapeutics CEO on harnessing the potential of mRNA engineering in cellular reprogramming, gene therapy and longevity.

Connecting the dots of longevity

Does SIRT6 hold the key to human longevity?

Therini Bio advances its first clinical candidate to treat Alzheimer’s

Getting comfortable with senotherapeutics

AI identifies three new antiaging senolytic candidates

Researchers engineer solution to extend cellular lifespan and slow aging

Rubedo announces first-in-class drug candidate for dermatology

New Alzheimer’s drug slows cognitive decline by a third

Flexible e-tattoo can spot early heart disease red flags

Pan-Biome reports positive results in gut microbiome modulator trial

Life Biosciences presents data demonstrating restoration of visual function in nonhuman primates

UNITY Biotech announces positive results from Phase 2 BEHOLD study on diabetic macular edema

Longevity: ‘money-spinning cult’ or the future of health?

Longevity investment: ‘Good companies will continue to get funded’

Mitochondrial therapy could tackle aging from the inside out

Shining a light on cardiovascular aging

More power to you – why energy could be the key to longevity

Rubedo presents in vivo efficacy data targeting senescent cells

New data suggest investigational osteoarthritis drug may have promising senotherapeutic effect

Retro: A longevity biotech triple-threat?

Cyclarity: When bad guy cells have a change of heart

Stressed tissue and cellular burn-out? Enter the Mitochondrial Cycle

Cambrian Bio reveals new pipeline company with focus on AMPK activation

First longevity clinical study design fetches FDA approval

Plant-derived osteoarthritis drug ready for further Phase 2 trials

Longevity company Biophysical Therapeutics emerges from stealth

Electrodes grown in the brain pave the way for future therapies for neurological disorders

Leonhardt Ventures and Lionheart Health file patent for bioelectric control of antiaging protein expression

Designing a molecule for longevity

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

First Longevity Ltd is an appointed representative of Prospect Capital Ltd which is authorised and regulated by the Financial Conduct Authority.
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.